IgG-Scaffolded IL-15 Tumor Targeting Service
Creative Biolabs offers a cutting-edge, fully customizable platform for biopharmaceutical researchers. We provide comprehensive molecule engineering, integrating the highly potent IgG-Scaffolded IL-15 for maximized targeting capability. The complete service ensures your immunocytokine asset is expertly de-risked and prepared for scale-up. Clients receive a robust, research-validated immunocytokine candidate designed to overcome the critical toxicity and short half-life limitations of native IL-15. This approach ensures a broader therapeutic index for your oncology research.
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Introduction of IgG-Scaffolded IL-15 Tumor Targeting Service
Interleukin-15 (IL-15) is a potent cytokine essential for the proliferation, differentiation, and survival of anti-tumor natural killer (NK) cells and cytotoxic CD8+T cells. While native IL-15 signaling is highly desirable for oncology research, its use is severely limited by rapid systemic clearance and dose-limiting toxicity due to non-specific activation of immune cells throughout the body. The IgG-scaffolded IL-15 superagonist complex resolves this issue by providing a targeted, trispecific therapeutic. This targeted delivery mechanism is critical for achieving a broader therapeutic index in oncology drug discovery and development.
For an in-depth analysis of how our services can be tailored to your specific project needs, we encourage you to discuss your concerns with us.
Fig.1 IL-15 agonists used in immunotherapy. 1
What We Can Offer
Customized Trispecific Scaffold Design
We perform tailored engineering of the IgG backbone, including rigorous isotype selection and optimized linker chemistry, to perfectly match your specific tumor-associated antigen (TAA) and maximize ADCC potentiation.
Optimized Upstream and Downstream Development
We provide efficient, customized process development strategies, running the fermentation process in batch, fed-batch, or continuous modes. This optimization maximizes both the yield and the final purity of the complex immunocytokine.
Cell Bank Stability Assurance
Rigorous documentation and verification procedures, assessed and approved by qualified quality assurance services, guarantee the stability of strains in cell banks and throughout large-scale fermentations. We ensure the stability of gene expression and prevent genetic drift across multiple passages.
How Creative Biolabs Can Assist Your Project
Why Choose Us?
|
Core Advantages
|
Unique Features
|
|
Safety Advantage
|
Confers a superior safety profile with minimal CRS risk in NHP models, allowing for higher, more effective localized concentrations at the tumor site in research.
|
|
Efficacy Advantage
|
Significantly increases the expression of cytotoxic molecules (granzyme B and perforin) in NK cells and CD8+ T cells, confirming robust anti-tumor immune activation.
|
|
Potency Advantage
|
Demonstrates greater potency in vivo compared to native IL-15, maximizing the therapeutic window and minimizing required protein mass.
|
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Customer Reviews
-
Exceptional TCM Expansion
Using Creative Biolabs' service in our research has significantly improved the analysis of antigen-independent cytotoxicity. The robust and preferential expansion of central memory T cells is a unique, powerful mechanism that native IL-15 cannot achieve alone, providing the critical efficacy data needed for our lead selection. - Dr. K****h A.
-
Reliable Half-Life Extension
Creative Biolabs' IgG-Scaffolded IL-15 tumor targeting service significantly facilitated the predictability of in vivo drug exposure. Their service fundamentally changes our dosing strategy and reduces required injection frequency, making longitudinal studies far simpler. - J. R****t.
FAQs
Q:
How does the IgG-Scaffolded IL-15 reduce the risk of cytokine release syndrome (CRS)?
A:
The key advantage of the IgG-Scaffolded IL-15, unlike traditional systemic cytokines like IL-2, is its ability to minimize the release of systemic pro-inflammatory cytokines. The IgG-scaffolded construct further improves this by concentrating the therapeutic effect within the tumor microenvironment (TME), significantly validating a low CRS risk in NHP models.
Q:
What is the primary functional difference between your IgG-Scaffolded IL-15 targeter and a simple IL-15 fusion protein?
A:
Our construct is trispecific: it targets the tumor via the IgG, delivers the highly potent IgG-Scaffolded IL-15 superagonist for T and NK cell signaling, and engages FcγR for enhanced ADCC. Crucially, it promotes the antigen-independent innate-like conversion of CD8+T cells, a unique mechanism that ensures robust, localized cytotoxicity not seen with simple fusions.
Related Services
Plasmid Manufacturing Service
Fast-track your preclinical studies with our high-quality plasmid production. This is essential for moving quickly to cell line development and advanced studies, ensuring regulatory compliance for your upstream materials.
Learn More →
FcR Binding Assay Service
A dedicated assay platform using label-free techniques (SPR, BLI) to analyze the binding kinetics of your construct to the neonatal Fc receptor (FcRn) for accurate half-life prediction and dosing.
Learn More →
How to Contact Us
Creative Biolabs delivers an enhanced, localized therapeutic effect with a favorable safety profile, paving the way for a broader therapeutic index and successful therapeutic development. Ready to discuss your TAA, accelerate your development timeline, and access the next generation of cytokine therapy? Please contact us.
Reference
-
Waldmann, Thomas A et al. "IL-15 in the Combination Immunotherapy of Cancer." Frontiers in immunology vol. 11 868. 19 May. 2020. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2020.00868
For Research Use Only | Not For Clinical Use
